Difference between revisions of "Abiraterone"

From Libre Pathology
Jump to navigation Jump to search
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Abiraterone''' is an androgen synthesis inhibitor used to treat [[prostate cancer]].<ref name=pmid23887973>{{Cite journal  | last1 = Mitsiades | first1 = N. | title = A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. | journal = Cancer Res | volume = 73 | issue = 15 | pages = 4599-605 | month = Aug | year = 2013 | doi = 10.1158/0008-5472.CAN-12-4414 | PMID = 23887973 }}</ref>
'''Abiraterone''' is an androgen synthesis inhibitor used to treat [[prostate cancer]].<ref name=pmid23887973>{{Cite journal  | last1 = Mitsiades | first1 = N. | title = A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. | journal = Cancer Res | volume = 73 | issue = 15 | pages = 4599-605 | month = Aug | year = 2013 | doi = 10.1158/0008-5472.CAN-12-4414 | PMID = 23887973 }}</ref>
==See also==
*[[Enzalutamide]].
*[[Prostate cancer]].
*[[Androgen receptor]].


==References==
==References==
Line 6: Line 11:
[[Category:Genitourinary pathology]]
[[Category:Genitourinary pathology]]
[[Category:Clinical]]
[[Category:Clinical]]
[[Category:Drugs]]

Latest revision as of 13:10, 18 March 2019

Abiraterone is an androgen synthesis inhibitor used to treat prostate cancer.[1]

See also

References

  1. Mitsiades, N. (Aug 2013). "A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.". Cancer Res 73 (15): 4599-605. doi:10.1158/0008-5472.CAN-12-4414. PMID 23887973.